Clinical effect of Qizhu capsules combined with empagliflozin in the treatment of patients with early diabetes kidney disease
Objective To explore the clinical effect of Qizhu capsules combined with empagliflozin in the treatment of patients with early diabetes kidney disease.Methods A total of 94 patients with early diabetes kidney disease admitted in our hospital from March 2020 to June 2022 were selected as the research objects.According to different treatment methods,the patients were divided into control group(47 cases,treated with empagliflozin)and observation group(47 cases,treated with Qizhu capsules combined with empagliflozin).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was 95.74%,which was higher than 78.72%in the control group(P<0.05).After treatment,the levels of fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PBG)and glycosylated hemoglobin(HbA1c)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of serum creatinine(SCr),blood urea nitrogen(BUN),24 h urine protein quantification,cystatin C(CysC),C1q and transferrin(TRF)in the observation group were lower than those in the control group(P<0.05).After treatment,the level of superoxide dismutase(SOD)in the observation group was higher than that in the control group,and the level of malonaldehyde(MDA)was lower than that in the control group(P<0.05).Conclusion Qizhu capsules combined with empagliflozin can reduce the blood glucose level of patients with early diabetes kidney disease,elevate renal function,and improve oxidative stress indicators.
NETL
NSTL
万方数据
